Zydus Cadila launches Mesalamine Delayed Release Tablets

In US market

Zydus Cadila has commercially launched its Mesalamine Delayed Release Tablets USP, 1.2 mg in the US market. Zydus was the first to file an Abbreviated New Drug Application for a generic version of Lialda and is currently the only generic available to patients in the US. The drug is indicated for the treatment of mild to moderate ulcerative colitis.

Powered by Capital Market - Live News